B7-H3 CAR-28z-T

B7-H3 CAR-28z-T (also referred to as B7-H3.CAR-28z-Ts) is a second-generation chimeric antigen receptor (CAR) T-cell therapy targeting CD276 (B7-H3). Developed by the University of North Carolina, Greensboro, this therapy consists of T cells genetically engineered to express a CAR construct that includes a B7-H3-specific single-chain variable fragment (scFv) fused to a CD28 costimulatory domain and a CD3ζ signaling domain. B7-H3 is an immune regulatory protein that is highly overexpressed in various solid tumors, such as pancreatic ductal adenocarcinoma, ovarian cancer, and neuroblastoma, while showing limited expression in normal tissues. Upon binding to B7-H3 on tumor cells, the CAR-T cells are activated to proliferate and exert cytotoxic effects. Although preclinical studies have shown efficacy in several solid tumor models, its development for pancreatic cancer is currently categorized as having no progress.

Other names

B7-H3.CAR-28z-TsB-7-H3.CAR-28z-TsB 7-H3.CAR-28z-TsB7-H3-targeting CD28-zeta CAR-T cellsB-7-H3-targeting CD28-zeta CAR-T cellsB 7-H3-targeting CD28-zeta CAR-T cells